

LINDA DWOSKIN, Ph.D.

Associate Professor
Pharmaceutical Sciences

Research Interests

Dr. Dvoskin's focus is the neuropsychopharmacology of the regulation of DA neuronal function, (i.e. control of DA release/reuptake into the presynaptic terminal, metabolism of DA, of dopamine (DA) functional responses induced by DA receptor stimulation, and the development of novel treatments for diseases involving DA pathophysiology, (i.e., Parkinson's disease, schizophrenia and drug abuse). DA is an important neurotransmitter for the control of motor movement, emotions. The role of genetics and environmental factors as determinants of responsiveness to drugs of abuse (psychostimulants: phencyclidine, amphetamine, cocaine and nicotine) and as determinants of abuse liability is a current focus.



Selected Research Publications/Presentations

Dvoskin LP, Buxton ST, Jewell AL and Crooks PA. S(-)Nornicotine increases dopamine release in a calcium-dependent manner from rat striatal slices. *J Neurochem*, 60:2167-2174, 1993.

Bardo MT, Bowling SL, Rowlett JK, Manderscheid P, Buxton ST and Dvoskin LP. Environmental enrichment attenuates locomotor sensitization, but not in vitro dopamine release induced by amphetamine. *Pharmacol Biochem and Behav*, 51:397-405, 1995.

Dvoskin LP, Teng LH, Buxton ST, Ravard A, Deo N and Crooks PA. Minor alkaloids of tobacco release [3H]dopamine from superfused rat striatal slices. *Eur J Pharmacol*, 276:195-199, 1995.

Crooks PA, Ravard A, Wilkins LH, Teng LH, Buxton ST and Dvoskin LP. Inhibition of nicotine-evoked [3H]dopamine release by pyridino N-substituted nicotine analogues: A new class of nicotinic antagonist. *Drug Dev Res*, 36:71-82, 1995.

Crooks PA, Li M and Dvoskin LP. Determination of nicotine metabolites in rat brain after peripheral radiolabelled nicotine administration: Detection of nornicotine. *Drug Metab and Dispo*, 23:1175-1177, 1995.